Morbidity | References | Incidence | Suspected agent | Mortality | Change in mortality3 | Utility4 | Change in morbidity5 | |
---|---|---|---|---|---|---|---|---|
 |  | SD | HD |  |  |  |  |  |
Therapy related leukaemia | [10, 22, 23] | 0.5% | 1.5% | Etoposide (< 2 g/m2, > 2 g/m2) | 70% | 0.7% | 0.90 | 0.03% |
Vascular toxicity | [10, 16, 24, 25] | Â | Â | Â | Â | Â | Â | Â |
Raynaud's phenomenon | Â | 25% | >25% | Bleomycin | Â | Â | - | - |
Cardiovascular disease | Â | 7% | 10% | Cisplatin | 10% | 0.3% | 0.7 | 0.81% |
Neurotoxicity | [5, 10, 21] | Â | Â | Â | Â | Â | Â | Â |
Peripheral neuropathy | Â | 4% | 5% | Cisplatin | Â | Â | - | - |
Ototoxicity | Â | 5% | 65% | Cisplatin (<400 mg/m2, > 400 mg/m2) | Â | Â | - | - |
Nephrotoxicity | [5, 10, 16] | Â | Â | Â | Â | Â | Â | Â |
Renal failure | Â | 1% | 4% | Cisplatin | Â | Â | 0.6 | 1.2% |
Hypertension | Â | 10% | 24% | Cisplatin (<400 mg/m2, > 400 mg/m2) | Â | Â | 0.99 | 0.14% |
Gonadal toxicity | [10, 16, 26, 41] | Â | Â | Â | Â | Â | Â | Â |
Infertility1 | Â | 50% | >50% | Cisplatin | Â | Â | Â | Â |
Sexual functioning2 | Â | 15% | 27% | Â | Â | Â | 0.92 | 0.96% |
Total | Â | Â | Â | Â | Â | 1% | Â | 3.14% |